Group 1 - The cannabis industry is experiencing increased speculation regarding the potential reclassification of cannabis from a Schedule 1 to a Schedule 3 substance, which could have significant implications for the market [1] - Comments regarding the reclassification gained credibility following statements made by President on August 11th, indicating a shift in regulatory perspective [1] Group 2 - The author of the article has extensive experience in finance and investment banking, including founding a nationwide investment banking firm and writing multiple publications on cannabis stocks [1]

Core Insights - Momentum investors focus on "buying high and selling higher" rather than traditional strategies of buying low and waiting for recovery [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [2] Group 1: Investment Strategy - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum [3] - The Zacks Momentum Style Score aids in identifying strong momentum stocks by analyzing price and earnings trends [3] Group 2: MariMed Inc. (MRMD) Analysis - MariMed Inc. (MRMD) has shown significant price momentum, with a four-week price change of 58% and a 12-week gain of 114.2% [4][5] - MRMD has a high beta of 3, indicating it moves 200% more than the market in either direction, suggesting strong volatility [5] - The stock has a Momentum Score of B, indicating a favorable time to invest [6] Group 3: Earnings and Valuation - MRMD has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investor interest [7] - The stock is currently trading at a Price-to-Sales ratio of 0.38, indicating it is undervalued at 38 cents for each dollar of sales [7] Group 4: Additional Opportunities - Besides MRMD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, which can help identify potential winning stocks [9]

Group 1 - Cannara Biotech Inc. has approved the grant of incentive awards under its stock option plan and restricted share unit compensation plan [1][2] - The awards were granted in alignment with the completion of the Company's fiscal year-end on August 31, 2025, marking five consecutive years of commercial operations and year-over-year revenue growth [2] - The Company has granted 3,625,000 stock options to certain employees, each exercisable into one common share at an exercise price of $1.44 per share, vesting over three years [5] Group 2 - Cannara operates two mega facilities in Québec, covering over 1,650,000 sq. ft., with a potential annualized cultivation output of 100,000 kg [4] - The Company leverages Québec's low electricity costs to produce premium-grade cannabis products at affordable prices [4] - 145,000 restricted share units (RSUs) were granted to members of the board of directors, vesting in full on the second anniversary of the grant date [5]

Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/1CKikEKnPj https://t.co/6Tfpp9jZZR ...

Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/6rpMTeiRZL https://t.co/klMy9TkOqE ...

Group 1 - The cannabis industry, including multi-state operator Cresco Labs, is facing significant challenges such as black- and gray-market competition, limited access to financial services, and high taxation [1][2] - Cresco Labs' stock performance has been poor, with a $1,000 investment in the stock shrinking to approximately $200 over the past five years, while the S&P 500 index would have grown to $1,878 in the same period [2] - The legal status of cannabis in the U.S. is complicated, with federal illegality contrasted by varying state laws, leading to a patchwork of legalization across the country [4] Group 2 - There is ongoing lobbying for federal rescheduling of marijuana, but it is not a priority for lawmakers, leaving companies like Cresco in a survival mode [5] - Cresco Labs is experiencing declining revenue and ongoing challenges with profitability, although it has recently refinanced a $325 million credit facility and holds $147 million in cash and equivalents [6]

Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/VTfsB854rd https://t.co/nJ8CQ14TOb ...

Meet The Ex-NASA Engineer Training Robots To Make Pre-Roll Joints https://t.co/8aEFkLa7WJ https://t.co/lC7ppqgJ7A ...

Core Points - AYR Wellness Inc. has executed a definitive senior secured bridge term loan agreement providing up to US$50 million in funding to support ongoing operations and facilitate a restructuring plan [1][3] - The Bridge Credit Agreement involves multiple draws and is secured by all present and future acquired assets of the Borrower and Guarantors, ranking pari passu with existing senior secured notes [5][6] - The loans under the Bridge Facility bear an interest rate of 14.0% per annum, with specific maturity dates for Tranche A and Tranche B loans [6][10] Financial Structure - The Bridge Facility consists of Initial Term Loans (Tranche A and Tranche B) and Delayed Draw Term Loans, with proceeds allocated for working capital, corporate purposes, and restructuring costs [4][3] - A commitment premium, exit premium, and backstop premium are included in the Bridge Facility, all payable in kind and potentially convertible to equity [7] Covenants and Conditions - The Bridge Credit Agreement includes affirmative and negative covenants, such as maintaining cannabis licenses and restrictions on additional indebtedness, with a minimum liquidity covenant of US$17.5 million [8] - Events of default include payment defaults, covenant breaches, and failure to meet restructuring milestones [9] Company Overview - AYR Wellness is a vertically integrated U.S. multi-state cannabis operator with over 90 licensed retail locations across several states, offering a broad portfolio of cannabis products [12]

Company Overview - Cheech & Chong, known for stoner comedy, have established a company in the cannabis industry [1] - The company sells THC-infused edibles, drinks, and cannabis [1] Financial Performance - The company's products generate significant revenue ("serious green") [1]